CN103463034A - Application of Lycojaponicumin B to medicament for treating oophoroma - Google Patents
Application of Lycojaponicumin B to medicament for treating oophoroma Download PDFInfo
- Publication number
- CN103463034A CN103463034A CN2013104361945A CN201310436194A CN103463034A CN 103463034 A CN103463034 A CN 103463034A CN 2013104361945 A CN2013104361945 A CN 2013104361945A CN 201310436194 A CN201310436194 A CN 201310436194A CN 103463034 A CN103463034 A CN 103463034A
- Authority
- CN
- China
- Prior art keywords
- lycojaponicumin
- application
- medicine
- oophoroma
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930185194 lycojaponicumin Natural products 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 16
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000012010 growth Effects 0.000 abstract description 7
- 108700024827 HOC1 Proteins 0.000 abstract description 6
- 101100178273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOC1 gene Proteins 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 241000927897 Lycopodium japonicum Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Lycojaponicumin B in preparation of a medicine for treating oophoroma, belonging to the technical field of new applications of medicines. According to the application disclosed by the invention, the in-vitro MTT (methyl thiazolyl tetrazolium) anti-tumor activity evaluation discovers that the Lycojaponicumin B also has an obvious inhibitory effect on the growth of human ovarian carcinoma cell lines including HO-8910, HOC1 and OVAC. Thus, the Lycojaponicumin B can be used for preparing an anti-oophoroma medicine and has good prospects in development and application. The application of the Lycojaponicumin B in preparation of medicine for treating oophoroma, disclosed by the invention, is disclosed for the first time. The skeleton type of the Lycojaponicumin B belongs to a brand new skeleton type, and the inhibitory activity of the Lycojaponicumin B on human ovarian carcinoma cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compound L ycojaponicumin B, relate in particular to the application of Lycojaponicumin B in preparing ovarian cancer resistance medicament.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be the natural product or derivatives thereof, as paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, searching anticancer compound or lead compound have great importance.
The compound L ycojaponicumin B the present invention relates to is one and within 2012, delivers (Wang, X. J. et al., 2012. Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum. Organic Letters 14 (10), 2614-2617.) New skeleton compound, this compound has brand-new framework types, purposes for the Lycojaponicumin B the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for ovarian cancer simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound L ycojaponicumin B in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Lycojaponicumin B in preparing ovarian cancer resistance medicament, and the structural formula of Lycojaponicumin B is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Lycojaponicumin B also has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC, suppresses the IC of this 3 strain Growth of Cells
50value is respectively 1.21 ± 0.11 μ M, 2.37 ± 0.14 μ M and 2.14 ± 0.12 μ M.Therefore, Lycojaponicumin B can, for the preparation of ovarian cancer resistance medicament, have good development prospect.
The purposes of the Lycojaponicumin B the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for ovarian cancer simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound L ycojaponicumin B involved in the present invention is referring to document (Wang, X. J. et al., 2012. Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum. Organic Letters 14 (10), 2614-2617.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L ycojaponicumin B tablet involved in the present invention:
Get 20 and digest compound Lycojaponicumin B, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound L ycojaponicumin B capsule involved in the present invention:
Get 20 and digest compound Lycojaponicumin B, add the conventional adjuvant for preparing capsule as starch 180 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Lycojaponicumin B to the human oophoroma cell line
1. method: in the cell of growth logarithmic (log) phase: human oophoroma cell line HO-8910, HOC1 and OVAC(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4the concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that the drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Lycojaponicumin B of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Lycojaponicumin B has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.This compound suppresses the IC of human oophoroma cell line HO-8910, HOC1 and OVAC growth
50value is respectively: 1.21 ± 0.11 μ M, 2.37 ± 0.14 μ M and 2.14 ± 0.12 μ M.
By above-described embodiment, shown, Lycojaponicumin B of the present invention has good inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.Prove thus, Lycojaponicumin B of the present invention has the ovarian cancer resistance activity, can be for the preparation of ovarian cancer resistance medicament.
Claims (1)
1.Lycojaponicumin the application of B in treatment ovarian cancer medicine, described compound L ycojaponicumin B structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310436194.5A CN103463034B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310436194.5A CN103463034B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103463034A true CN103463034A (en) | 2013-12-25 |
| CN103463034B CN103463034B (en) | 2015-12-02 |
Family
ID=49788232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310436194.5A Active CN103463034B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463034B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
-
2013
- 2013-09-23 CN CN201310436194.5A patent/CN103463034B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| XIAO-JING WANG, ET AL: "Lycojaponicumins A-c,Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum", 《ORGANIC LETTERS》, vol. 14, no. 10, 8 May 2012 (2012-05-08), pages 2614 - 2617, XP055066237, DOI: 10.1021/ol3009478 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103463034B (en) | 2015-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463046A (en) | Application of Lycojaponicumin A in drugs for treating colorectal cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN103463034A (en) | Application of Lycojaponicumin B to medicament for treating oophoroma | |
| CN103463024A (en) | Application of Lycojaponicumin B in medicine for treating kidney cancer | |
| CN103463020A (en) | Application of Lycojaponicumin A in medicine for treating kidney cancer | |
| CN103463051A (en) | Application of Lycojaponicumin A in medicaments for treating nasopharyngeal cancer | |
| CN103463022A (en) | Application of Lycojaponicumin B in medicine for treating ileocecum cancer | |
| CN103463054A (en) | Application of Lycojaponicumin A in medicaments for treating bladder cancer | |
| CN103463027A (en) | Application of Lycojaponicumin A in medicine for treating laryngocarcinoma | |
| CN103463052A (en) | Application of Lycojaponicumin A in drugs for treating cervical cancer | |
| CN103463056A (en) | Application of Lycojaponicumin A in drugs for treating tongue cancer | |
| CN103494812A (en) | Application of Lycojaponicumin A in drug for treating ovarian cancer | |
| CN103463050A (en) | Application of Lycojaponicumin A in medicine for treating gastric cancer | |
| CN103479633A (en) | Application of Lycojaponicumin B in preparation of drugs for treating nasopharyngeal carcinoma | |
| CN103463049A (en) | Application of Lycojaponicumin B in medicine for treating breast cancer | |
| CN103463065A (en) | Application of Lycojaponicumin C in preparation of medicines for treating skin cancer | |
| CN103463032A (en) | Application of Lycojaponicumin A in medicine for treating pancreatic cancer | |
| CN103463041A (en) | Application of Lycojaponicumin B in medicine for treating bladder cancer | |
| CN103463070A (en) | Application of Lycojaponicumin C in preparation of medicines for treating breast cancer | |
| CN103463033A (en) | Application of Lycojaponicumin B in medicine for treating gastric cancer | |
| CN103463078A (en) | Application of Lycojaponicumin C in medicine for treating kidney cancer | |
| CN103463062A (en) | Application of Lycojaponicumin C in preparation of medicines for treating colorectal cancer | |
| CN103479632A (en) | Application of Lycojaponicumin B in preparation of drugs for treating cervical carcinoma | |
| CN103463044A (en) | Application of Lycojaponicumin A in drugs for treating skin cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Hongli Inventor before: Jiang Chunping Inventor before: Zhang Guang |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151103 Address after: 325011, building 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Zhejiang, Wenzhou Applicant after: Wenzhou Chengqiao Technology Co.,Ltd. Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Applicant before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181221 Address after: 210000 Central Road, Gulou District, Nanjing City, Jiangsu Province, 399 Patentee after: Deng Ying Address before: 325011 room 1112, building A, 209 Wenchang Road, hi tech Zone, Longwan District, Wenzhou, Zhejiang. Patentee before: Wenzhou Chengqiao Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190402 Address after: 233090 Zhongchuang Space A-43, 1st Floor, Chuangchuang Space, No. 8 Roadway 2595, Donghai Avenue, Bengbu City, Anhui Province Patentee after: Bengbu Yongyuan Electronic Technology Co., Ltd. Address before: 210000 Central Road, Gulou District, Nanjing City, Jiangsu Province, 399 Patentee before: Deng Ying |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191216 Address after: 233200 Jinshan Road Electronic Commerce Industrial Park, Jingkai District, Dingyuan County, Chuzhou City, Anhui Province Patentee after: Anhui Creative Technology Transfer Service Co.,Ltd. Address before: 233090 Zhongchuang Space A-43, 1st Floor, Chuangchuang Space, No. 8 Roadway 2595, Donghai Avenue, Bengbu City, Anhui Province Patentee before: Bengbu Yongyuan Electronic Technology Co., Ltd. |
|
| TR01 | Transfer of patent right |